Author

L. Maloney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Animal Behavior & Cognition· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. M. Smith· 2 shared J. E. Maxson· 2 shared S. A. Carratt· 2 shared T. P. Braun· 2 shared Z. Schonrock· 2 shared A. Baris· 1 shared A. Foley· 1 shared B. J. Druker· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. M. Smith

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Using influence measures to test normative use of probability density information derived from a sample

K. Ota, L. Maloney

The paper tests how humans use probability density information in decision-making by comparing their performance to Bayesian decision theory predictions, finding systematic deviations in influence measures.

bioRxiv · Feb 5, 2023 · PreprintAnimal Behavior & Cognition

Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms

S. A. Carratt, G. L. Kong, B. M. Smith, Z. Schonrock, L. Maloney, A. Baris, B. J. Druker, T. P. Braun, J. E. Maxson

This study shows that mutant SETBP1 promotes aggressive myeloproliferative neoplasms by upregulating Myc and its target genes, which can be reversed by epigenetic drugs.

bioRxiv · Nov 4, 2021Cancer Biology

Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

S. A. Carratt, T. P. Braun, C. Coblentz, Z. Schonrock, R. Callahan, B. M. Smith, L. Maloney, A. Foley, J. E. Maxson

This study shows that SETBP1 mutations enhance NRAS-driven MAPK signaling in leukemia, making cells sensitive to MEK inhibitor trametinib.

bioRxiv · Feb 1, 2021Cancer Biology